EA026389B1 - Замещенные аналоги (e)-n'-(1-фенилэтилиден)бензогидразида в качестве ингибиторов деметилазы гистонов - Google Patents

Замещенные аналоги (e)-n'-(1-фенилэтилиден)бензогидразида в качестве ингибиторов деметилазы гистонов Download PDF

Info

Publication number
EA026389B1
EA026389B1 EA201490453A EA201490453A EA026389B1 EA 026389 B1 EA026389 B1 EA 026389B1 EA 201490453 A EA201490453 A EA 201490453A EA 201490453 A EA201490453 A EA 201490453A EA 026389 B1 EA026389 B1 EA 026389B1
Authority
EA
Eurasian Patent Office
Prior art keywords
compound
accordance
compounds
another aspect
mao
Prior art date
Application number
EA201490453A
Other languages
English (en)
Russian (ru)
Other versions
EA201490453A1 (ru
Inventor
Харипрасад Ванкайалапати
Венкатасвами Сорна
Стив Л. Уорнер
Дэвид Дж. Бирсс
Сунил Шарма
Брет Стефенс
Original Assignee
Юниверсити Оф Юта Рисерч Фаундейшн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Юниверсити Оф Юта Рисерч Фаундейшн filed Critical Юниверсити Оф Юта Рисерч Фаундейшн
Publication of EA201490453A1 publication Critical patent/EA201490453A1/ru
Publication of EA026389B1 publication Critical patent/EA026389B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/45—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the singly-bound nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfonamides
    • C07C311/46—Y being a hydrogen or a carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • C07D295/26—Sulfur atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
EA201490453A 2011-08-15 2012-08-15 Замещенные аналоги (e)-n'-(1-фенилэтилиден)бензогидразида в качестве ингибиторов деметилазы гистонов EA026389B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161523801P 2011-08-15 2011-08-15
PCT/US2012/050948 WO2013025805A1 (en) 2011-08-15 2012-08-15 Substituted (e)-n'-(1-phenylethylidene) benzohydrazide analogs as histone demethylase inhiitors

Publications (2)

Publication Number Publication Date
EA201490453A1 EA201490453A1 (ru) 2014-09-30
EA026389B1 true EA026389B1 (ru) 2017-04-28

Family

ID=47715455

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201490453A EA026389B1 (ru) 2011-08-15 2012-08-15 Замещенные аналоги (e)-n'-(1-фенилэтилиден)бензогидразида в качестве ингибиторов деметилазы гистонов

Country Status (26)

Country Link
US (2) US8987335B2 (enExample)
EP (1) EP2744330B1 (enExample)
JP (1) JP6122006B2 (enExample)
KR (1) KR101983537B1 (enExample)
CN (1) CN103929960B (enExample)
AU (1) AU2012296639B2 (enExample)
BR (1) BR112014003382B1 (enExample)
CA (1) CA2843609C (enExample)
CY (1) CY1123345T1 (enExample)
DK (1) DK2744330T3 (enExample)
EA (1) EA026389B1 (enExample)
ES (1) ES2821548T3 (enExample)
HK (1) HK1200052A1 (enExample)
HR (1) HRP20201433T1 (enExample)
HU (1) HUE050962T2 (enExample)
IL (1) IL230728A (enExample)
IN (1) IN2014CN00961A (enExample)
LT (1) LT2744330T (enExample)
MX (1) MX356486B (enExample)
PL (1) PL2744330T3 (enExample)
PT (1) PT2744330T (enExample)
SG (1) SG2014009609A (enExample)
SI (1) SI2744330T1 (enExample)
SM (1) SMT202000551T1 (enExample)
WO (1) WO2013025805A1 (enExample)
ZA (1) ZA201400881B (enExample)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9266838B2 (en) 2011-08-15 2016-02-23 University Of Utah Research Foundation Substituted (E)-N′-(1-phenylethylidene)benzohydrazide analogs as histone demethylase inhibitors
DK2903968T3 (en) 2012-10-02 2017-01-30 Gilead Sciences Inc INHIBITORS OF HISTON DEMETHYLASES
EP3170811A1 (en) 2013-02-27 2017-05-24 Gilead Sciences, Inc. Ethyl pyridine-4-carboxylate compound as inhibitor of histone demethylases
EP2968282B1 (en) * 2013-03-12 2018-05-09 Celgene Quanticel Research, Inc. Histone dementhylase inhibitors
ES2739814T3 (es) 2013-06-19 2020-02-04 Univ Utah Res Found Compuestos de (3-(5-cloro-2-hidroxifenil)-1-benzoil-1H-pirazol sustituidos como inhibidores de histona desmetilasa
US9493442B2 (en) 2014-02-13 2016-11-15 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
WO2015123437A1 (en) 2014-02-13 2015-08-20 Incyte Corporation Cyclopropylamines as lsd1 inhibitors
PE20161384A1 (es) 2014-02-13 2016-12-28 Incyte Corp Ciclopropilaminas como inhibidores de lsd 1
ME03654B (me) 2014-02-13 2020-07-20 Incyte Corp Ciklopropilamini kao lsd1 inhibitori
US10807944B2 (en) 2014-04-04 2020-10-20 University Of Florida Research Foundation, Inc. HDAC inhibitor compounds and methods of treatment
JP2017518312A (ja) * 2014-06-05 2017-07-06 ユニバーシティ・オブ・カンザス マルメリン類似体および癌治療における使用方法
WO2016007722A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines and triazolopyrazines as lsd1 inhibitors
WO2016007736A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Imidazopyrazines as lsd1 inhibitors
WO2016007727A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines and triazolopyrazines as lsd1 inhibitors
US9695168B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted imidazo[1,5-α]pyridines and imidazo[1,5-α]pyrazines as LSD1 inhibitors
CN107074807A (zh) 2014-08-27 2017-08-18 吉利德科学公司 用于抑制组蛋白脱甲基酶的组合物和方法
EP2993175A1 (en) 2014-09-05 2016-03-09 IEO - Istituto Europeo di Oncologia Srl Thienopyrroles as histone demethylase inhibitors
CN106146361A (zh) * 2015-03-16 2016-11-23 四川大学 茚-1-亚基磺酰基苯甲酰肼衍生物及其制备方法和用途
MX373154B (es) 2015-04-03 2020-04-22 Incyte Holdings Corp Compuestos heterocíclicos como inhibidores de demetilasa 1 específica de lisina (lsd1).
CN107849611A (zh) 2015-06-12 2018-03-27 奥瑞泽恩基因组学股份有限公司 与lsd1抑制剂相关的生物标志物及其用途
WO2017013061A1 (en) 2015-07-17 2017-01-26 Oryzon Genomics, S.A. Biomarkers associated with lsd1 inhibitors and uses thereof
MX389824B (es) 2015-08-12 2025-03-20 Incyte Holdings Corp Sales de un inhibidor de dimetilasa 1 especifica para lisina (lsd1).
JP7158023B2 (ja) 2016-03-15 2022-10-21 オリソン ヘノミクス エセ． アー． 固形腫瘍の治療における使用のための、ｌｓｄ１阻害剤の組合せ
EP3430015B9 (en) 2016-03-16 2025-12-31 Oryzon Genomics, S.A. METHODS FOR DETERMINING THE ENGAGEMENT OF A KDM1A TARGET AND CORRESPONDING USEFUL CHEMOPROBE
EP3445339B1 (en) 2016-04-22 2023-08-23 Incyte Corporation Formulations of an lsd1 inhibitor
EP3246330A1 (en) 2016-05-18 2017-11-22 Istituto Europeo di Oncologia S.r.l. Imidazoles as histone demethylase inhibitors
US11427543B2 (en) 2016-07-19 2022-08-30 The General Hospital Corporation Compounds for targeting cancer stem cells
EP3535414A1 (en) 2016-11-03 2019-09-11 Oryzon Genomics, S.A. Pharmacodynamic biomarkers for personalized cancer care using epigenetic modifying agents
EP3535420A1 (en) 2016-11-03 2019-09-11 Oryzon Genomics, S.A. Biomarkers for determining responsiveness to lsd1 inhibitors
US20200069677A1 (en) 2016-12-09 2020-03-05 Constellation Pharmaceuticals, Inc. Markers for personalized cancer treatment with lsd1 inhibitors
CN106831489B (zh) * 2017-03-23 2018-04-17 郑州大学 苯环丙胺酰腙类化合物、制备方法及其应用
SG11202000077RA (en) 2017-08-03 2020-02-27 Oryzon Genomics Sa Methods of treating behavior alterations
EP3668877B1 (en) 2017-08-18 2024-05-01 Istituto Europeo di Oncologia S.r.l. Indole derivatives as histone demethylase inhibitors
WO2019068326A1 (en) 2017-10-05 2019-04-11 Université D'aix-Marseille INHIBITORS OF LSD1 FOR THE TREATMENT AND PREVENTION OF CARDIOMYOPATHIES
RS63124B1 (sr) 2018-03-08 2022-05-31 Incyte Corp Aminopirazin diol jedinjenja kao pi3k-y inhibitori
WO2020010003A1 (en) 2018-07-02 2020-01-09 Incyte Corporation AMINOPYRAZINE DERIVATIVES AS PI3K-γ INHIBITORS
WO2020047198A1 (en) 2018-08-31 2020-03-05 Incyte Corporation Salts of an lsd1 inhibitor and processes for preparing the same
CN109793742A (zh) * 2019-03-04 2019-05-24 四川大学华西医院 一种药物化合物应用
CN113631164A (zh) 2019-03-20 2021-11-09 奥莱松基因组股份有限公司 使用kdm1a抑制剂如化合物伐菲德司他治疗注意缺陷多动症的方法
CN113613653A (zh) 2019-03-20 2021-11-05 奥莱松基因组股份有限公司 治疗边缘型人格障碍的方法
CN109758442B (zh) * 2019-03-20 2021-08-17 武汉大学 二芳基酰肼类化合物在制备抗流感病毒药物中的应用
JP2022546908A (ja) 2019-07-05 2022-11-10 オリゾン・ゲノミクス・ソシエダッド・アノニマ Ｋｄｍ１ａ阻害剤を使用した小細胞肺がんの個別化された処置のためのバイオマーカーおよび方法
US20220047528A1 (en) * 2020-07-24 2022-02-17 Salarius Pharmaceuticals Llc Methods of inhibiting lysine-specific demethylase 1 (lsd-1)
EP3964204A1 (en) 2020-09-08 2022-03-09 Université d'Aix-Marseille Lsd1 inhibitors for use in the treatment and prevention of fibrosis of tissues
TW202304416A (zh) 2021-04-08 2023-02-01 西班牙商奧萊松基因組股份有限公司 用於治療骨髓癌的ｌｓｄ１抑制劑的組合
US20250295660A1 (en) 2022-05-09 2025-09-25 Oryzon Genomics, S.A. Methods of treating nf1-mutant tumors using lsd1 inhibitors
JP2025516647A (ja) 2022-05-09 2025-05-30 オリゾン・ゲノミクス・ソシエダッド・アノニマ Ｌｓｄ１阻害薬を用いる悪性末梢神経鞘腫（ｍｐｎｓｔ）の治療法
CN116077661B (zh) * 2022-08-22 2024-09-27 沈阳药科大学 Kdm1a抑制剂在制备治疗dnmt3a基因缺失癌症的药物中的用途
AU2023385514A1 (en) 2022-11-24 2025-07-10 Oryzon Genomics, S.A. Combinations of lsd1 inhibitors and menin inhibitors for treating cancer

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040110963A1 (en) * 2001-01-22 2004-06-10 Kaspar Burri Novel hydrazones
US20080269206A1 (en) * 2007-04-02 2008-10-30 Institute For Oneworld Health Cftr inhibitor compounds and uses thereof
US20090247641A1 (en) * 2005-08-26 2009-10-01 Lee Roy Morgan Hydrazone agents to treat cutaneous lesions
US20100247543A1 (en) * 2007-08-24 2010-09-30 Oryzon Genomics, S.A. Treatment and prevention of neurodegenerative diseases

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002302472A (ja) * 2001-01-31 2002-10-18 Meiji Seika Kaisha Ltd メイラード反応阻害剤
EP1649852A1 (en) 2003-07-16 2006-04-26 Institute of Medicinal Molecular Design, Inc. Chromatosis remedies
WO2006136008A1 (en) 2005-05-24 2006-12-28 University Health Network Salicylic acid hydrazones as inhibitors of the erk mapkinase pathway and for the treatment of cancer
RU2008115539A (ru) 2005-11-03 2009-12-10 Рэдпойнт Био Корпорэйшн (Us) Производные гидразона и их применение
US8338464B2 (en) 2006-11-30 2012-12-25 Albert Einstein College Of Medicine Of Yeshiva University Small molecule inhibitors of BCL6
JP2010518008A (ja) 2007-02-02 2010-05-27 レッドポイント バイオ コーポレイション インスリンおよびｇｌｐ−１の放出を調節するｔｒｐｍ５阻害物質
AR070898A1 (es) * 2008-03-18 2010-05-12 Solvay Pharm Bv Derivados de arilsulfonil pirazolin carboxamidina como antagonistas de 5-ht6
CA2729766A1 (en) 2008-07-01 2010-01-07 Zacharon Pharmaceuticals, Inc. Heparan sulfate inhibitors
BRPI1006843A2 (pt) * 2009-01-14 2017-05-30 Dow Agrosciences Llc composições fungicidas incluindo derivados de hidrazona e cobre
CA2727890A1 (en) 2010-01-13 2011-07-13 Norbert Kartner Compounds, compositions and treatments for v-atpase related diseases

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040110963A1 (en) * 2001-01-22 2004-06-10 Kaspar Burri Novel hydrazones
US20090247641A1 (en) * 2005-08-26 2009-10-01 Lee Roy Morgan Hydrazone agents to treat cutaneous lesions
US20080269206A1 (en) * 2007-04-02 2008-10-30 Institute For Oneworld Health Cftr inhibitor compounds and uses thereof
US20100247543A1 (en) * 2007-08-24 2010-09-30 Oryzon Genomics, S.A. Treatment and prevention of neurodegenerative diseases

Also Published As

Publication number Publication date
US8987335B2 (en) 2015-03-24
PT2744330T (pt) 2020-10-01
MX356486B (es) 2018-05-30
BR112014003382A2 (pt) 2017-11-21
AU2012296639B2 (en) 2016-06-09
SMT202000551T1 (it) 2020-11-10
IN2014CN00961A (enExample) 2015-04-10
MX2014001842A (es) 2014-07-24
IL230728A (en) 2017-05-29
US20150150864A1 (en) 2015-06-04
SI2744330T1 (sl) 2020-11-30
CA2843609A1 (en) 2013-02-21
AU2012296639A1 (en) 2014-03-06
LT2744330T (lt) 2020-10-26
EP2744330B1 (en) 2020-07-15
IL230728A0 (en) 2014-03-31
CA2843609C (en) 2020-12-08
JP6122006B2 (ja) 2017-04-26
WO2013025805A1 (en) 2013-02-21
HRP20201433T1 (hr) 2020-12-11
PL2744330T3 (pl) 2020-12-14
CN103929960B (zh) 2016-08-17
ZA201400881B (en) 2015-07-29
JP2014527531A (ja) 2014-10-16
US9555024B2 (en) 2017-01-31
SG2014009609A (en) 2014-05-29
HK1200052A1 (en) 2015-07-31
HUE050962T2 (hu) 2021-01-28
EP2744330A1 (en) 2014-06-25
CY1123345T1 (el) 2022-03-24
US20140094445A1 (en) 2014-04-03
KR20140077887A (ko) 2014-06-24
EA201490453A1 (ru) 2014-09-30
ES2821548T3 (es) 2021-04-26
DK2744330T3 (da) 2020-09-07
NZ621078A (en) 2015-10-30
KR101983537B1 (ko) 2019-05-29
EP2744330A4 (en) 2015-03-25
CN103929960A (zh) 2014-07-16
BR112014003382B1 (pt) 2022-03-15

Similar Documents

Publication Publication Date Title
EA026389B1 (ru) Замещенные аналоги (e)-n'-(1-фенилэтилиден)бензогидразида в качестве ингибиторов деметилазы гистонов
KR102288648B1 (ko) 히스톤 데메틸라제 억제제로서의 치환된 (e)-n′-(1-페닐에틸리덴)벤조하이드라지드 동족체
US8569511B2 (en) Substituted 3-(1H-benzo[d]imidazol-2-yl)-1H-indazole analogs as inhibitors of the PDK1 kinase
RU2753056C2 (ru) Бициклические гетероарильные производные в качестве стимуляторов cftr
BR112018001469B1 (pt) Composto, composição farmacêutica e uso de um composto
JP2013544891A (ja) ｍＧＬＵＲ５受容体のアロステリック調節剤としての二環式ピラゾール化合物
EP2819662B1 (en) Reprogramming effector protein interactions to correct epigenetic defects in cancer
US9642857B2 (en) Substituted (E)-N′-(1-phenylethylidene)benzohydrazide analogs as histone demethylase inhibitors
US20170119795A1 (en) Fused triterpene compounds and uses thereof
NZ621078B2 (en) Substituted (e)-n'-(1-phenylethylidene) benzohydrazide analogs as histone demethylase inhibitors